Statute Details
- Title: Healthcare Services (Nuclear Medicine Service) Regulations 2023
- Act Code: HSA2020-S412-2023
- Type: Subsidiary legislation (SL)
- Authorising Act: Healthcare Services Act 2020 (made under section 57)
- Legislative Instrument No.: S 412/2023
- Commencement: 26 June 2023
- Status: Current version (as at 27 Mar 2026)
- Parts: Part 1 (Preliminary) to Part 10 (Miscellaneous)
- Key Themes: licensing compliance; personnel competence and governance; quality management; radiation safety; patient safeguards; anaesthetics/sedatives; imaging and reporting; in vivo assay specimen/test controls; therapy protocols; outsourcing prohibition; records; price transparency; offences and revocation
- Notable Provisions (from extract): s 5 (specified services); s 6 (prohibited service delivery modes); ss 7–12 (personnel requirements); ss 13–14 (quality and equipment); ss 15–23 (safety programmes and patient-specific safeguards); ss 39–51 (imaging handling and reporting); ss 53–68 (in vivo assay specimen/test accuracy and reporting); ss 70–71 (therapy counselling and protocols); ss 72–78 (outsourcing, records, price transparency, financial counselling); ss 79–80 (offences and revocation)
What Is This Legislation About?
The Healthcare Services (Nuclear Medicine Service) Regulations 2023 (“Nuclear Medicine Regulations”) set out detailed, operational requirements for providers of nuclear medicine services in Singapore. In plain terms, the Regulations aim to ensure that nuclear medicine is delivered safely, competently, and with appropriate safeguards for patients—particularly because these services involve ionising radiation, radiopharmaceuticals, and (in many cases) invasive procedures, imaging with contrast agents, or therapeutic administration.
The Regulations sit under the broader regulatory framework of the Healthcare Services Act 2020. They translate high-level licensing and governance expectations into specific rules about staffing, quality systems, equipment, radiation safety programmes, clinical processes, and reporting obligations. They also address patient protections for vulnerable groups (including pregnant women and children), and require prompt communication of urgent findings and errors.
Practically, the Regulations distinguish between different “purposes” of nuclear medicine services—imaging, in vivo assay, and therapy—and impose additional requirements tailored to each purpose. This structure matters for compliance: a provider’s obligations will vary depending on what it actually does (and how it does it), not merely on its general authorisation to operate.
What Are the Key Provisions?
1) Scope, specified services, and prohibited delivery modes
The Regulations begin by defining their scope and key terms. Section 5 identifies the “specified services” for the purposes of section 9A(1) of the Healthcare Services Act 2020. This is critical because the Act’s licensing regime can hinge on whether a provider is offering a “specified service”. Section 6 then prohibits certain “service delivery modes”. While the extract does not reproduce the full text of s 6, the existence of a prohibition indicates that not all delivery models are permissible—e.g., certain arrangements may be barred even if the provider has the relevant licence.
2) Personnel competence and governance
Part 2 focuses on people. Sections 7 and 8 require qualifications, skills, and competencies of a Clinical Governance Officer, and set out that officer’s duties and responsibilities. Sections 9 and 10 deal with the appointment of a section leader and that leader’s duties. Section 11 provides general requirements relating to personnel, while section 12 addresses “specific personnel” (again, the extract indicates there are further categories or roles with tailored requirements).
For practitioners advising healthcare operators, the key compliance point is that governance is not optional. The Regulations require named roles (Clinical Governance Officer and section leader) and impose duties that support safe service delivery. In enforcement terms, personnel-related breaches can be easier for regulators to evidence because they often involve documentary proof (appointment records, qualifications, competency evidence) and observable operational practice.
3) Quality management and equipment/fittings
Part 3 requires a quality management system (s 13) and sets requirements for equipment and fittings (s 14). These provisions reflect a systems approach: providers must not only have competent staff but also maintain processes and infrastructure to ensure consistent, safe outcomes. In nuclear medicine, equipment performance and maintenance are central to radiation safety and diagnostic/therapeutic reliability.
4) Radiation and patient safety programmes
Part 4 is the safety core. Sections 15 and 16 require a safety programme and a radiation safety programme. Section 17 then requires the licensee to ensure personnel comply with safety plans and programmes. Section 18 mandates that personal protective equipment must be provided. Section 19 addresses the administration and use of radiopharmaceuticals, which is a high-risk activity requiring strict controls.
Sections 20–23 provide patient-specific and emergency preparedness safeguards. These include requirements relating to pregnant women (s 20), patients aged 12 years or younger (s 21), adjunctive measures (s 22), and ensuring essential life-saving measures are available (s 23). For counsel, these provisions are particularly important for clinical risk management and incident response planning. They also influence consent processes and clinical protocols, because the Regulations effectively require additional safeguards for certain patient groups and for high-risk scenarios.
5) Anaesthetics and sedatives
Part 5 governs the administration and use of anaesthetics and sedatives in the context of nuclear medicine services. It includes definitions (s 24), general requirements (s 25), and specific requirements for an anaesthesia service (s 26) and that specified anaesthetic must be suitable for the patient (s 27). It also covers nursing services (s 28), essential life-saving measures (s 29), post-procedure care (s 30), recovery and observation areas (s 31), discharge (s 32), and post-discharge follow-up (s 33).
These provisions are likely to be scrutinised during audits and investigations because they intersect with sedation-related adverse events and patient monitoring. They also require providers to have appropriate physical spaces and discharge processes, not merely clinical competence.
6) Imaging: handling, safeguards, referral, and reporting
Part 7 adds requirements for nuclear medicine services for imaging purposes. Section 39 applies this Part. Division 1 covers service delivery mechanics: handling of images (s 40), general safeguards for examinations (s 41), and a referral requirement before service is provided (s 42). It also addresses administration and use of contrast agents (s 43) and records for examinations (s 44).
Division 2 then focuses on reporting. Sections 46–47 require written imaging reports and specify their contents (s 47). Sections 48–51 require urgent notification of results in emergencies, identification and review of incidental or abnormal findings, notification of errors, and processes to ensure prompt reporting. This is a key legal risk area: failure to report urgently or to correct errors can expose providers to regulatory action and potential civil liability.
7) In vivo assay: specimen/test controls and accuracy
Part 8 imposes additional requirements for nuclear medicine services for in vivo assay purposes. Division 1 includes a referral requirement (s 53), specimen acceptance/rejection (s 54), handling and transport of specimens (s 55), and a central requirement that applicable tests must be accurate (s 56). It also requires standards for reagents (s 57), documentation relating to applicable tests (s 58), quality control of applicable tests (s 59), and records for specimens and applicable tests (ss 60–61).
Division 2 addresses reporting: written clinical laboratory reports (s 63), contents (s 64), urgent notification in emergencies (s 65), review of incidental/abnormal findings (s 66), notification of errors (s 67), and prompt reporting processes (s 68). For practitioners, the emphasis on accuracy, quality control, and documentation is likely to be decisive in disputes about test reliability or delayed reporting.
8) Therapy: counselling and post-treatment protocols
Part 9 covers nuclear medicine services for therapy purposes. It requires pre-treatment counselling and assessment (s 70) and post-treatment protocols (s 71). These provisions align with patient safety and informed decision-making, and they also support continuity of care after therapy—an area where adverse outcomes can arise if follow-up is inadequate.
9) Miscellaneous compliance: outsourcing, records, and transparency
Part 10 includes important operational and commercial compliance measures. Section 72 provides that outsourcing is prohibited, which is a significant constraint: providers must deliver the regulated service themselves rather than subcontracting key functions. Sections 73–74 require records relating to conduct of examinations, performance of in vivo assay procedures, provision of treatment, and other matters. Sections 75–76 require price transparency and display of charges. Sections 77–78 require disclosure of approved institution status and financial counselling.
Finally, ss 79–80 address offences and revocation. These provisions underline that non-compliance can lead to criminal or regulatory consequences and, in serious cases, loss of authorisation.
How Is This Legislation Structured?
The Regulations are organised into ten Parts. Part 1 (Preliminary) sets out citation/commencement, definitions, application, notification of addition/removal of purposes for which nuclear medicine services are provided, identification of specified services, and prohibited service delivery modes. Part 2 addresses personnel requirements (governance officer, section leader, and staff requirements). Part 3 covers processes, equipment, and fittings through quality management and equipment standards. Part 4 sets safety requirements, including radiation safety programmes and patient-specific safeguards. Part 5 governs anaesthetics and sedatives. Part 6 covers testing of specimens and ultrasound imaging. Parts 7–9 provide additional, purpose-specific requirements for imaging, in vivo assay, and therapy respectively, including referral rules, handling, reporting, and emergency notification. Part 10 contains miscellaneous compliance obligations (outsourcing prohibition, records, price transparency, financial counselling) and enforcement provisions (offences and revocation).
Who Does This Legislation Apply To?
The Regulations apply to a licensee providing a nuclear medicine service at approved premises. The obligations are framed around the licensee’s duty to ensure compliance across staffing, systems, safety programmes, clinical processes, and reporting. The Regulations also apply to relevant categories of personnel involved in delivering the service, because many duties are expressed as requirements that the licensee must ensure personnel comply with.
In addition, the purpose-based structure means that providers must assess which additional Part applies to their actual service offerings: imaging, in vivo assay, and/or therapy. A provider offering multiple purposes must comply with each corresponding set of additional requirements, including the distinct reporting and documentation rules.
Why Is This Legislation Important?
For legal practitioners, these Regulations are important because they create a detailed compliance framework that can be used to assess whether a nuclear medicine provider met the standard expected by regulators. The Regulations are not merely administrative; they impose substantive clinical governance and patient safety duties—particularly around radiation safety programmes, radiopharmaceutical administration, sedation/anaesthesia controls, and urgent reporting of results and errors.
From an enforcement perspective, the Regulations’ structure supports evidence-based oversight. Many obligations require written reports, specified record-keeping, documented quality control, and named roles. This makes it easier for regulators to investigate incidents and for counsel to evaluate compliance gaps.
Commercially and operationally, the outsourcing prohibition (s 72) and price transparency requirements (ss 75–76) affect how providers structure service delivery and interact with patients. Financial counselling and disclosure of approved institution status (ss 77–78) also create additional duties that can influence complaints and disputes.
Related Legislation
- Healthcare Services Act 2020
- Healthcare Services (General) Regulations 2021
- Allied Health Professions Act 2011
- Medical Registration Act 1997
- Radiation Protection Act 2007
Source Documents
This article provides an overview of the Healthcare Services (Nuclear Medicine Service) Regulations 2023 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.